Switch from extended half-life factor VIII to emicizumab in a poorly controlled hemophilia A patient: a case report
Revista Hemostasia y Trombosis · 16.09.2026 · 2 (2)
DOI: 10.24875/rht.25000009 ↗Kurz gefasst
Fallbericht in der Zeitschrift Revista Hemostasia y Trombosis, online erschienen am 16.09.2026. Verfasst von Ana R. Cid-Haro und 5 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Cid-Haro, A. R., Poveda-Andrés, J. L., Megías-Vericat, J. E., Choví-Trull, M., Bonanad-Boix, S., & Haya-Guaita, S. (2026). Switch from extended half-life factor VIII to emicizumab in a poorly controlled hemophilia A patient: a case report. Revista Hemostasia y Trombosis, 2(2). https://doi.org/10.24875/rht.25000009
Vancouver
Cid-Haro AR, Poveda-Andrés JL, Megías-Vericat JE, Choví-Trull M, Bonanad-Boix S, Haya-Guaita S. Switch from extended half-life factor VIII to emicizumab in a poorly controlled hemophilia A patient: a case report. Revista Hemostasia y Trombosis. 2026;2(2). doi:10.24875/rht.25000009
BibTeX
@article{CidHaro2026,
author = {Cid-Haro, Ana R. and Poveda-Andrés, Jose L. and Megías-Vericat, Juan E. and Choví-Trull, Maria and Bonanad-Boix, Santiago and Haya-Guaita, Saturnino},
title = {Switch from extended half-life factor VIII to emicizumab in a poorly controlled hemophilia A patient: a case report},
journal = {Revista Hemostasia y Trombosis},
year = {2026},
volume = {2},
number = {2},
doi = {10.24875/rht.25000009}
}
EUVIMED